gemcitabine has been researched along with 3,3'-diindolylmethane in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, A; Azmi, AS; Banerjee, S; Mohammad, RM; Rangnekar, VM; Sarkar, FH | 1 |
| Banerjee, S; Kong, D; Sarkar, FH; Wang, Z | 1 |
| Ali, S; Kong, D; Li, Y; Philip, PA; Sarkar, FH; VandenBoom, TG; Wang, Z | 1 |
| Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM | 1 |
4 other study(ies) available for gemcitabine and 3,3'-diindolylmethane
| Article | Year |
|---|---|
Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Receptors, Thrombin; Signal Transduction; Up-Regulation | 2008 |
3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytochromes c; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Cell Dedifferentiation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Indoles; Isoflavones; Mesoderm; MicroRNAs; Pancreatic Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2009 |
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |